BRD3

Across TCGA pan-cancer cohorts, BRD3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BRD3 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher BRD3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated BRD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, SARC, and LIHC are the cancer types where BRD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.945	0.473	.009	32	view →
SARC	OS	Median	All	0.126	0.860	<.001	16	view →
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
LUAD	OS	Median	All	0.141	0.788	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BRD3–UCEC (DFS)

Open the UCEC breakdown →